600161.SS SHH
Beijing Tiantan Biological Products Co., Ltd.
1W: +1.9%
1M: +2.9%
3M: +4.7%
YTD: -23.7%
1Y: -37.9%
3Y: -38.6%
5Y: -43.0%
¥12.59 ($1.88)
+0.47 (+3.88%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$16.6B
+4.8% ▲
5Y CAGR: +17.1%
Total Liabilities
$1.2B
-8.7% ▼
5Y CAGR: -4.2%
Shareholders Equity
$11.7B
+5.4% ▲
5Y CAGR: +21.0%
Cash & Investments
$2.0B
-25.9% ▼
5Y CAGR: +2.6%
Total Debt
$187M
+317.5% ▲
5Y CAGR: -25.2%
Net Debt
-$1.8B
+31.7% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $4.3B | $3.7B | $4.6B | $2.7B | $2.0B |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Cash & ST Investments | $4.3B | $3.7B | $4.6B | $2.7B | $2.0B |
| Net Receivables | $1.0B | $1.2B | $133M | $1.1B | $2.2B |
| Inventory | $2.1B | $2.3B | $2.8B | $3.9B | $4.0B |
| Other Current Assets | $45M | $53M | $1M | $2M | $15M |
| Total Current Assets | $7.5B | $7.3B | $7.6B | $7.7B | $8.3B |
| Property, Plant & Equip. | $2.6B | $4.1B | $5.0B | $5.8B | $5.9B |
| Goodwill & Intangibles | $829M | $1.1B | $1.2B | $1.9B | $2.0B |
| Long-Term Investments | $254M | $218M | $146M | $143M | $202M |
| Other Non-Current Assets | $251M | $221M | $197M | $235M | $97M |
| Total Non-Current Assets | $4.0B | $5.7B | $6.6B | $8.1B | $8.4B |
| Total Assets | $11.6B | $12.9B | $14.2B | $15.9B | $16.6B |
| — Liabilities — | |||||
| Accounts Payable | $74M | $69M | $179M | $81M | $81M |
| Short-Term Debt | $0 | $113M | $0 | $0 | $119M |
| Deferred Revenue | $605M | $293M | $0 | $0 | $178M |
| Other Current Liabilities | $131M | $682M | $386M | $229M | $446M |
| Total Current Liabilities | $810M | $1.2B | $1.3B | $1.1B | $1.0B |
| Long-Term Debt | $366M | $254M | $0 | $0 | $0 |
| Other Non-Current Liab. | $97M | $4M | $101M | $1M | $1M |
| Total Non-Current Liabilities | $501M | $427M | $154M | $216M | $186M |
| Total Liabilities | $1.3B | $1.6B | $1.4B | $1.3B | $1.2B |
| — Equity — | |||||
| Common Stock | $1.4B | $1.6B | $1.6B | $2.0B | $2.0B |
| Retained Earnings | $3.4B | $4.1B | $5.1B | $6.4B | $7.0B |
| Accumulated OCI | $350M | $356M | $0 | $0 | $438M |
| Total Stockholders Equity | $8.1B | $8.8B | $9.8B | $11.1B | $11.7B |
| Total Liabilities & Equity | $11.6B | $12.9B | $14.2B | $15.9B | $16.6B |
| — Key Metrics — | |||||
| Total Debt | $509M | $403M | $24M | $45M | $187M |
| Net Debt | -$3.8B | -$3.3B | -$4.5B | -$2.6B | -$1.8B |
| Total Investments | $254M | $218M | $146M | $143M | $202M |